OncoMatch/Clinical Trials/CNS Lymphoma (PCNSL)
CNS Lymphoma (PCNSL) Clinical Trials
OncoMatch filters CNS Lymphoma (PCNSL) trials by the molecular markers that determine eligibility — MYD88, CD79B, and more. Enter your biomarker results to see only the trials you may qualify for.
Compare eligibility criteriaTop recruiting CNS Lymphoma (PCNSL) trials
Ranked by phase and number of US sites. See all trials matched to your profile →
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Dana-Farber Cancer Institute
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Estrella Biopharma, Inc.
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
Baptist Health South Florida
Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma
Hyungwoo Cho
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
How OncoMatch finds CNS Lymphoma (PCNSL) trials for you
AI reads the protocol
Every CNS Lymphoma (PCNSL) trial on ClinicalTrials.gov has eligibility criteria written for regulators. OncoMatch uses large language models to extract the structured requirements — biomarkers, stage, prior therapy, and more — from that text.
You enter your results
Select CNS Lymphoma (PCNSL) and mark your biomarker results — MYD88, CD79B — as positive, negative, or not tested. Your data never leaves your device.
See only relevant trials
Results filter instantly. Each trial shows exactly which criteria you meet, which you don't, and which need more information. Bring the list to your oncologist.